MX2017010595A - Métodos, composiciones, y equipos para tratamiento de cáncer. - Google Patents
Métodos, composiciones, y equipos para tratamiento de cáncer.Info
- Publication number
- MX2017010595A MX2017010595A MX2017010595A MX2017010595A MX2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A
- Authority
- MX
- Mexico
- Prior art keywords
- kits
- compositions
- cancer
- treatment
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000012270 PD-1 inhibitor Substances 0.000 abstract 2
- 239000012668 PD-1-inhibitor Substances 0.000 abstract 2
- 229940121655 pd-1 inhibitor Drugs 0.000 abstract 2
- 229940125832 FGFR3 inhibitor Drugs 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118350P | 2015-02-19 | 2015-02-19 | |
| US201562150235P | 2015-04-20 | 2015-04-20 | |
| PCT/US2016/018634 WO2016134234A1 (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017010595A true MX2017010595A (es) | 2018-11-12 |
Family
ID=56689191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010595A MX2017010595A (es) | 2015-02-19 | 2016-02-19 | Métodos, composiciones, y equipos para tratamiento de cáncer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160243228A1 (OSRAM) |
| EP (1) | EP3258966A4 (OSRAM) |
| JP (2) | JP6774421B2 (OSRAM) |
| KR (1) | KR20170137717A (OSRAM) |
| CN (1) | CN107635583A (OSRAM) |
| AU (2) | AU2016219917B2 (OSRAM) |
| BR (1) | BR112017017700A2 (OSRAM) |
| CA (1) | CA2976638A1 (OSRAM) |
| IL (1) | IL253979B (OSRAM) |
| MX (1) | MX2017010595A (OSRAM) |
| SG (1) | SG11201706727XA (OSRAM) |
| WO (1) | WO2016134234A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010229994B2 (en) | 2009-03-25 | 2016-08-18 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| KR102479696B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Fgfr 억제제 및 igf1r 억제제의 조합물 |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| MX370099B (es) | 2014-03-26 | 2019-12-02 | Astex Therapeutics Ltd | Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer. |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| KR102691777B1 (ko) | 2015-09-23 | 2024-08-02 | 얀센 파마슈티카 엔브이 | 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도 |
| CA2996857C (en) | 2015-09-23 | 2024-05-21 | Janssen Pharmaceutica Nv | Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer |
| RU2730503C2 (ru) | 2015-12-17 | 2020-08-24 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения рака молочной железы |
| AU2018215794A1 (en) * | 2017-02-06 | 2019-07-25 | Fusion Pharmaceuticals Inc. | Methods, compositions, and kits for treatment of cancer |
| CN108440673B (zh) * | 2018-04-08 | 2021-08-17 | 海南医学院 | Fc融合蛋白PD1/FGFR1及其应用 |
| US20200277387A1 (en) * | 2019-03-01 | 2020-09-03 | Rainier Therapeutics, Inc. | Methods and compositions for treating cancer |
| KR20220016803A (ko) * | 2019-06-03 | 2022-02-10 | 퓨전 파마슈티칼즈 인크. | 암을 치료하기 위한 방법 및 조성물 |
| KR20220070243A (ko) * | 2019-09-26 | 2022-05-30 | 얀센 파마슈티카 엔.브이. | 순차적 치료 환경에서 면역 체크포인트 억제제에 대한 환자 반응을 향상시키기 위한 fgfr-유전적으로 변경된 암에서의 fgfr 억제제의 용도 |
| BR112022019226A2 (pt) * | 2020-03-23 | 2022-11-08 | Fusion Pharmaceuticals Inc | Radioimunoconjugados direcionados a fgfr3 e usos dos mesmos |
| EP4200019A1 (en) | 2020-08-21 | 2023-06-28 | Genzyme Corporation | Fgfr3 antibodies and methods of use |
| CN116390757A (zh) * | 2020-10-28 | 2023-07-04 | 卫材R&D管理有限公司 | 用于治疗肿瘤的药物组合物 |
| EP4649092A1 (en) | 2023-01-13 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI381848B (zh) * | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
| AU2010229994B2 (en) * | 2009-03-25 | 2016-08-18 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
| US8754114B2 (en) * | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| KR20150037876A (ko) * | 2012-07-27 | 2015-04-08 | 제넨테크, 인크. | Fgfr3 관련 상태의 치료 방법 |
| DK3021869T3 (da) * | 2013-07-16 | 2020-09-21 | Hoffmann La Roche | Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere |
-
2016
- 2016-02-19 WO PCT/US2016/018634 patent/WO2016134234A1/en not_active Ceased
- 2016-02-19 CN CN201680022780.7A patent/CN107635583A/zh active Pending
- 2016-02-19 EP EP16753128.4A patent/EP3258966A4/en not_active Withdrawn
- 2016-02-19 AU AU2016219917A patent/AU2016219917B2/en active Active
- 2016-02-19 US US15/048,030 patent/US20160243228A1/en not_active Abandoned
- 2016-02-19 MX MX2017010595A patent/MX2017010595A/es unknown
- 2016-02-19 CA CA2976638A patent/CA2976638A1/en active Pending
- 2016-02-19 SG SG11201706727XA patent/SG11201706727XA/en unknown
- 2016-02-19 BR BR112017017700A patent/BR112017017700A2/pt not_active Application Discontinuation
- 2016-02-19 KR KR1020177025882A patent/KR20170137717A/ko not_active Ceased
- 2016-02-19 JP JP2017544657A patent/JP6774421B2/ja active Active
-
2017
- 2017-08-14 IL IL253979A patent/IL253979B/en active IP Right Grant
-
2020
- 2020-10-02 JP JP2020167443A patent/JP7122357B2/ja active Active
-
2022
- 2022-01-13 AU AU2022200196A patent/AU2022200196B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL253979B (en) | 2021-06-30 |
| AU2022200196A1 (en) | 2022-02-10 |
| JP6774421B2 (ja) | 2020-10-21 |
| KR20170137717A (ko) | 2017-12-13 |
| JP2018507220A (ja) | 2018-03-15 |
| WO2016134234A1 (en) | 2016-08-25 |
| AU2022200196B2 (en) | 2025-04-10 |
| JP7122357B2 (ja) | 2022-08-19 |
| EP3258966A4 (en) | 2018-07-25 |
| AU2016219917A1 (en) | 2017-09-07 |
| JP2021020909A (ja) | 2021-02-18 |
| SG11201706727XA (en) | 2017-09-28 |
| IL253979A0 (en) | 2017-10-31 |
| US20160243228A1 (en) | 2016-08-25 |
| CN107635583A (zh) | 2018-01-26 |
| NZ735243A (en) | 2024-11-29 |
| EP3258966A1 (en) | 2017-12-27 |
| AU2016219917B2 (en) | 2021-12-16 |
| BR112017017700A2 (pt) | 2018-07-31 |
| CA2976638A1 (en) | 2016-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017010595A (es) | Métodos, composiciones, y equipos para tratamiento de cáncer. | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12019502379A1 (en) | Pd-1/pd-l1 inhibitors | |
| EP4234551A3 (en) | Pyridazinones as parp7 inhibitors | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| PH12016501550B1 (en) | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer | |
| TW201611847A (en) | Compounds and compositions for treating EGFR expressing tumors | |
| AU2016263598A8 (en) | Methods and kits for treating depression | |
| IL280158A (en) | Methods of treating cancer with the PI3K inhibitor, GDC-0077 | |
| PH12015502091A1 (en) | Cdc7 inhibitors | |
| MX369691B (es) | Inhibidores de glutaminasa y métodos de empleo. | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| MX2021006326A (es) | Inhibidores de pcna. | |
| IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
| AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| EP3630080A4 (en) | USE OF EZH2 INHIBITORS TO TREAT CANCER | |
| MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
| PH12018501943A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
| MX388409B (es) | Composiciones y metodos para tratar canceres. | |
| PH12017501880A1 (en) | Methods for treating cancer | |
| MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. | |
| MX2015013021A (es) | 5-bromo-indirrubinas. | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof |